| Schedule of Basic and Biluted Net Loss Per Share |
The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to ASP Isotopes Inc. shareholders before deemed dividend on warrant to purchase common stock |
|
$ |
(75,062,857 |
) |
|
$ |
(8,932,925 |
) |
|
$ |
(83,509,054 |
) |
|
$ |
(15,881,010 |
) |
Deemed dividend on warrant to purchase common stock |
|
|
— |
|
|
|
(2,779,659 |
) |
|
|
— |
|
|
|
(2,779,659 |
) |
Net loss attributable to ASP Isotopes Inc. shareholders |
|
|
(75,062,857 |
) |
|
|
(11,712,584 |
) |
|
|
(83,509,054 |
) |
|
|
(18,660,669 |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common stock outstanding, basic and diluted |
|
|
73,009,938 |
|
|
|
49,136,009 |
|
|
|
71,256,809 |
|
|
|
46,848,926 |
|
Net loss per share, basic and diluted |
|
|
(1.03 |
) |
|
|
(0.24 |
) |
|
|
(1.17 |
) |
|
|
(0.40 |
) |
|
| Schedule of Antidilutive Securities |
The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
As of June 30, |
|
|
|
2025 |
|
|
2024 |
|
Options to purchase common stock |
|
|
2,431,000 |
|
|
|
2,731,000 |
|
Restricted stock |
|
|
4,754,156 |
|
|
|
2,550,000 |
|
Warrants to purchase common stock |
|
|
221,519 |
|
|
|
1,446,519 |
|
Total shares of common stock equivalents |
|
|
7,406,675 |
|
|
|
6,727,519 |
|
|